Patients with estrogen receptor-positive breast cancer constitute a major clinical population who are at higher risk for bone metastases and have higher rate of both relapse to the bone and late-onset bone metastasis [35], potentially owing to the higher levels of RANKL expressed by MDA-MB-231 cells, compared to that by the MCF-7 cells [36]. The gene discussed is ESR1; the disease is breast carcinoma.